1. Home
  2. SCNI vs SYTA Comparison

SCNI vs SYTA Comparison

Compare SCNI & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCNI
  • SYTA
  • Stock Information
  • Founded
  • SCNI 2003
  • SYTA N/A
  • Country
  • SCNI Israel
  • SYTA Canada
  • Employees
  • SCNI N/A
  • SYTA N/A
  • Industry
  • SCNI Biotechnology: Biological Products (No Diagnostic Substances)
  • SYTA Telecommunications Equipment
  • Sector
  • SCNI Health Care
  • SYTA Telecommunications
  • Exchange
  • SCNI Nasdaq
  • SYTA Nasdaq
  • Market Cap
  • SCNI 3.5M
  • SYTA 2.9M
  • IPO Year
  • SCNI N/A
  • SYTA 2020
  • Fundamental
  • Price
  • SCNI $2.84
  • SYTA $1.27
  • Analyst Decision
  • SCNI
  • SYTA
  • Analyst Count
  • SCNI 0
  • SYTA 0
  • Target Price
  • SCNI N/A
  • SYTA N/A
  • AVG Volume (30 Days)
  • SCNI 12.9K
  • SYTA 7.4M
  • Earning Date
  • SCNI 11-29-2024
  • SYTA 11-14-2024
  • Dividend Yield
  • SCNI N/A
  • SYTA N/A
  • EPS Growth
  • SCNI N/A
  • SYTA N/A
  • EPS
  • SCNI N/A
  • SYTA N/A
  • Revenue
  • SCNI $284,000.00
  • SYTA $11,988,979.00
  • Revenue This Year
  • SCNI N/A
  • SYTA $78.40
  • Revenue Next Year
  • SCNI N/A
  • SYTA $18.06
  • P/E Ratio
  • SCNI N/A
  • SYTA N/A
  • Revenue Growth
  • SCNI N/A
  • SYTA 41.59
  • 52 Week Low
  • SCNI $2.23
  • SYTA $0.76
  • 52 Week High
  • SCNI $8.92
  • SYTA $90.90
  • Technical
  • Relative Strength Index (RSI)
  • SCNI 30.31
  • SYTA 51.67
  • Support Level
  • SCNI $2.91
  • SYTA $1.17
  • Resistance Level
  • SCNI $3.70
  • SYTA $1.29
  • Average True Range (ATR)
  • SCNI 0.21
  • SYTA 0.14
  • MACD
  • SCNI -0.07
  • SYTA 0.02
  • Stochastic Oscillator
  • SCNI 7.37
  • SYTA 44.19

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

About SYTA Siyata Mobile Inc.

Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.

Share on Social Networks: